Hydrogel Endovascular Aneurysm Treatment Trial

Not Applicable

Completed

Conditions: Cerebral Aneurysm

Interventions: Device: HydroCoil Embolic System
Device: Control (bare platinum coils)

Registration Number: NCT01407952

Lead Sponsor: Northwestern University

Brief Summary: This research study is being done to test the effectiveness of a new generation FDA approved device for treating aneurysms compared to the current standard device for endovascular aneurysm treatment which is bare platinum coils. Endovascular procedures are a form of minimally invasive surgery, which is performed on blood vessels. The technique involves the introduction of a catheter which is a long, thin, flexible, hollow plastic tube through the skin into a large blood vessel. Typically the chosen blood vessel is the femoral artery found near the groin. The catheter is then maneuvered through the body to the location of the aneurysm in the brain using image guidance. Coils are delivered into the aneurysm through the catheters. Once the coils are delivered in the aneurysm, they are detached from the catheter. This is repeated until enough coils fill the aneurysm, blocking the blood flow to the aneurysm. The body responds by forming blood clots around the coil(s), which helps block the flow of blood into the aneurysm and keeps the vessel from rupturing or leaking. This study will compare the study device to the standard bare platinum coil to see which is better at preventing future rupturing or leaking. The study device is called the HydroCoil Embolization System and this study is a post-market clinical trial.

About 600 subjects from multiple institutions will take part in this study.

Detailed Description: Your part in this study will last up to 24 months and will involve 6 visits (1 baseline visit before your surgery, the surgical procedure and 4 follow-up visits). These visits will occur at the same time as the visits you would receive as standard of care after your surgery.

If you are in this study, you will be placed in one of two study groups by chance using a process similar to the flip of a coin. This process is called randomization. Neither you nor the study staff will select the group you will be in. One group, the control group, will have their aneurysm treated by the bare platinum coils during their endovascular procedure. The other group, the study group will receive coils from the HydroCoil Embolization System. Both groups will receive the same standard of care and follow-up, but during the surgery different types of coils will be used.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 600

Inclusion Criteria

Candidates for this study must meet the following criteria to be enrolled in the study:

Patient is between 18 and 75 years of age (inclusive).
Patient has a documented untreated intracranial saccular aneurysm 3-14 mm diameter angiographic lumen, ruptured or unruptured, suitable for embolization with coils.
Patients presenting with a HUNT and HESS Grade 0-3 or improving to such a grade before treatment
Any type of bare platinum coils and HydroCoil ® Coils are treatment options (all shapes allowed).
Patient or next of kin or person with appropriate power of attorney has provided written informed consent.
Patient is willing and available for study follow-up visits
Patient has not been previously entered into this Study

Exclusion Criteria

Candidates will be ineligible for enrollment in the study if any of the following conditions apply:

Inability to obtain informed consent
Patient is < 18 or > 75 years old
Target aneurysm is not saccular in nature (mycotic, fusiform, dissecting).
Target aneurysm is > 14 mm maximum luminal dimension, < 3 mm maximum luminal dimension
Target aneurysm has been previously clipped or coiled
Target aneurysm is in the physician's estimate unlikely to be successfully treated by endovascular techniques.
Patient has known hypersensitivity to platinum, nickel, stainless steel or structurally related compounds found in HydroCoil®, HydroSoft®, HydroFrame® Coils and/or bare platinum coils.
Baseline Hunt and Hess scale 4 or 5 for ruptured aneurysms
Intended use of a flow diverting stent (e.g. pipeline)
Subject has concurrent intracranial pathology, e.g.
- Moyamoya
- Vasculitis documented by biopsy results
- AVMs
- AV fistulas
- Significant atherosclerotic disease (i.e. symptomatic and or >50% narrowing of the parent arteries necessary to traverse in order to coil the target aneurysm)
- Intracranial Hematoma (unrelated to the target aneurysm)
- Brain tumors
- Vascular tortuosity and other conditions preventing access to target aneurysm
Subject has serious co-morbidities that could confound the study results:
- Uncontrolled hypertension
- Uncorrectable coagulation abnormality
- Contraindications for heparin, aspirin or clopidogrel
- Uncontrolled Diabetes Mellitus
- Organ failure of kidney, liver, heart, or lung
- Myocardial infarction within the past 6 months
- Cancer likely to cause death within 2 years or less.
Subject history indicates high risk of non-compliance (e.g., substance abuse, psychosocial issues, etc.)
Subject has a known history contraindicating contrast dye or iodine that cannot be pre-medicated prior to coiling procedure (vs. sensitivity which can be safely controlled by antihistamine, steroid, etc.). Medical clearance will be needed for this issue.
Patients who are unable to complete scheduled follow up assessments at the enrolling center due to limited life expectancy (<2 years), co-morbidities or geographical considerations
Subject is currently breast feeding, pregnant or plans to become pregnant in the next 2 years.
Major surgical procedure or trauma within 30 days prior to randomization
The patient is currently enrolled in another clinical study (device or drug).
More than one aneurysm needing treatment at the same time.

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
HydroCoil Embolic System	HydroCoil Embolic System	Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
Control	Control (bare platinum coils)	Aneurysm treatment using bare platinum coil(s)

Primary Outcome Measures

Name	Time	Method
Number of Patients With Aneurysm Recurrence Post Surgery	post surgery to 24 months	Defined as any progression on the Raymond-Roy (RR) Aneurysm Occlusion Scale. The RR scale is such that 1=complete occlusion, 2=residual neck, and 3=residual aneurysm.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events Related to the Procedure and/or the Device by Participant at Any Time in the Study.	24 months	number of participants who experienced any peri-procedural or post-procedural Adverse Event noted to be related to the procedure or device.
Total Number of Peri-procedural and Post-procedural Adverse Events Related to the Procedure and/or the Device.	24 months	total number of Adverse Events per person that were noted to be related to the procedure and device during the study
Number of Patients Who Needed Re-treatment of Target Aneurysm	24 months	During the 24 month follow-up, if Aneurysm needed to be re-treated.
Number of Participants Who Progressed on the Meyers Scale	24 months	Occlusion (in)stability was determined by progression on the Meyers scale. The Meyer scale is a 6-point grading scale based on the percentage of the aneurysm filled by contrast on DSA. Grade zero indicates complete and total aneurysm occlusion without remnant or in-terstitial filling within the aneurysm. Grade 1 represents greater than 90%volumetric occlusion of the aneurysm based on planar imaging assessment; grade 2, 70%-89% aneurysm occlusion; grade 3,50%-69%; grade 4, 25%-49%; and grade 5, less than 25% volumetric aneurysm occlusion.
Packing Density	at operation	Packing density as measured by volumetric filling of the aneurysm
Clinical Outcome: Modified Rankin Scale (mRS)	24 months	modified rankin scale is a measure of neurological disability, which ranges from 0=no symptoms to 5=severe disability (6=dead).
Number of Patients Who Expired During the Study (Mortality Rate)	24 months	all-cause mortality at any time during study follow-up
Number of Participants With Initial Complete Occlusion	at procedure	Raymond-Roy (RR) Scale=1 at procedure The RR scale is such that 1=complete occlusion, 2=residual neck, and 3=residual aneurysm.
Number of Participants Experiencing a Hemorrhage From Target Aneurysm Post Surgery	24 months	Per the Adverse event log, if a hemorrhage or rupture occurred that was noted to be related to the procedure or device at any point during the 24 month follow-up (not during the operation).
Number of Participants Experiencing Major Versus Minor Recurrence by 24 Months Follow-up.	24 months	Major recurrence is defined as progression on the Raymond-Roy (RR) Scale to 3, or if initial RR was 3, then progression on the Meyers scale. Minor recurrence was defined as a progression on the RR scale to 2. The RR scale is a 3 point measure of occlusion, 1=total, 2=residual neck, and 3=residual aneurysm. The Meyer scale is a 6-point grading scale based on the percentageof the aneurysm filled by contrast on DSA. Grade zero indicates complete and total aneurysm occlusion without remnant or in-terstitial filling within the aneurysm. Grade 1 represents \>90%volumetric occlusion of the aneurysm based on planar imaging assessment; grade 2, 70%-89% aneurysm occlusion; grade 3,50%-69%; grade 4, 25%-49%; and grade 5, \<25% volumetric aneurysm occlusion.

Trial Locations

Locations (43): SUNY Upstate Medical University
🇺🇸
Syracuse, New York, United States
Massachusetts General Hospital
🇺🇸
Boston, Massachusetts, United States
Methodist Hospital Research Institute
🇺🇸
Houston, Texas, United States
University of Minnesota
🇺🇸
Minneapolis, Minnesota, United States
Christiana Hospital
🇺🇸
Newark, Delaware, United States
Kaiser Permanente NW
🇺🇸
Clackamas, Oregon, United States
Washington University
🇺🇸
Saint Louis, Missouri, United States
Advocate Health
🇺🇸
Oak Lawn, Illinois, United States
Baptist Cardiac and Vascular Institute
🇺🇸
Miami, Florida, United States
University of Maryland
🇺🇸
Baltimore, Maryland, United States
Capital Health Regional Medical Center
🇺🇸
Trenton, New Jersey, United States
Northwestern University
🇺🇸
Chicago, Illinois, United States
Albany Medical College
🇺🇸
Albany, New York, United States
SUNY Stony Brook
🇺🇸
Stony Brook, New York, United States
UPMC Hamot
🇺🇸
Erie, Pennsylvania, United States
Cleveland Clinic
🇺🇸
Cleveland, Ohio, United States
Ohio State University
🇺🇸
Columbus, Ohio, United States
McGill Universtiy
🇨🇦
Montreal, Quebec, Canada
CHU de Quebec
🇨🇦
Quebec, Canada
University of Virginia
🇺🇸
Charlottesville, Virginia, United States
West Virginia University
🇺🇸
Morgantown, West Virginia, United States
University of Saskatchewan
🇨🇦
Saskatoon, Saskatchewan, Canada
CHUM Research Centre
🇨🇦
Montreal, Quebec, Canada
Hamilton Health/McMaster Univeristy
🇨🇦
Hamilton, Ontario, Canada
Dalhousie Univerisity
🇨🇦
Halifax, Nova Scotia, Canada
Oregon Health and Science University
🇺🇸
Portland, Oregon, United States
St. Joseph's Hospital
🇺🇸
Phoenix, Arizona, United States
Mayo Clinic
🇺🇸
Rochester, Minnesota, United States
Oklahoma University Health Sciences Center
🇺🇸
Oklahoma City, Oklahoma, United States
Columbia University
🇺🇸
New York, New York, United States
Lyerly Neurosurgery
🇺🇸
Jacksonville, Florida, United States
Consulting Radiologists, LTD
🇺🇸
Minneapolis, Minnesota, United States
East Carolina University
🇺🇸
Greenville, North Carolina, United States
MultiCare Health System
🇺🇸
Tacoma, Washington, United States
Kaiser Permanente Sacramento
🇺🇸
Sacramento, California, United States
Medical University of South Carolina
🇺🇸
Charleston, South Carolina, United States
Mercy General Hospital
🇺🇸
Sacramento, California, United States
University of Michigan
🇺🇸
Ann Arbor, Michigan, United States
Queens Medical Center
🇺🇸
Honolulu, Hawaii, United States
University of Louisville
🇺🇸
Louisville, Kentucky, United States
Norton Healthcare
🇺🇸
Louisville, Kentucky, United States
Thomas Jefferson University
🇺🇸
Philadelphia, Pennsylvania, United States
Rhode Island Hospital
🇺🇸
Providence, Rhode Island, United States

Hydrogel Endovascular Aneurysm Treatment Trial

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts